comparemela.com

Latest Breaking News On - Prostate specific membrane antigen targeted - Page 6 : comparemela.com

Blue Earth Diagnostics Highlights Upcoming Presentation of Additional Results from Investigational Phase 3 SPOTLIGHT Study of PET Imaging Agent 18F-rhPSMA-7 3 in Biochemical Recurrence of Prostate Cancer

- Results to be presented at American Urological Association's 2023 Annual Meeting (AUA2023) - Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization

Mccormick placeUnited statesUnited kingdomPriscilla harlanScintomics gmbBriant helfandMike beyerClare gidleyNorthshore university healthsystemBracco groupAmerican urological associationNuclear medicineStudy groupCorporate communicationsCompany at boothDivision of urology

Blue Earth Diagnostics Highlights Upcoming Presentation of Additional Results from Investigational Phase 3 LIGHTHOUSE Study

Results of the Investigational Phase 3 LIGHTHOUSE Study of 18F-rhPSMA-7.3 in newly diagnosed prostate cancer to be presented at 2023 ASCO Genitourinary Cancers Symposium (ASCO GU)

United statesSan franciscoScintomics gmbBrianf chapinUniversity of texas md anderson cancer centerStudy groupDivision of surgeryTechnical university of munichDuke university medical centerDepartment of urologyBlue earth diagnostic medical affairsBlue earth diagnosticsCancers symposiumProstate specific membrane antigen targetedEmission tomographyAdvanced prostate cancer

Blue Earth Diagnostics Announces Efficacy and Safety Results from Phase 3 LIGHTHOUSE Trial of Investigational PET Imaging Agent 18F-rhPSMA-7 3 in Newly Diagnosed Prostate Cancer

First results from LIGHTHOUSE trial presented at 23rd Annual Scientific Meeting in Urologic Oncology (SUO)

San diegoUnited statesScintomics gmbDavide gaudenBrianf chapinTechnical university of munichDivision of surgeryUniversity of texas md anderson cancer centerDepartment of urologyDrug administrationStudy groupBlue earth diagnosticsProstate specific membrane antigen targetedAnnual scientific meetingUrologic oncologyAssociate professor

Blue Earth Diagnostics Announces Efficacy and Safety Results from Phase 3 LIGHTHOUSE Trial of Invest

− First results from LIGHTHOUSE trial presented at 23rd Annual Scientific Meeting in Urologic Oncology (SUO) –MONROE TOWNSHIP, N.J. & OXFORD, England (BUSINESS WIRE) Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, today.

United statesUnited kingdomSan diegoScintomics gmbDavide gaudenBrianf chapinClare gidleyMike beyerPriscilla harlanUniversity of texas md anderson cancer centerDrug administrationStudy groupSam brown incBracco groupDivision of surgeryTechnical university of munich

Blue Earth Diagnostics Announces Efficacy and Safety Results from Phase 3 LIGHTHOUSE Trial of Investigational PET Imaging Agent 18F-rhPSMA-7 3 in Newly Diagnosed Prostate Cancer

- First results from LIGHTHOUSE trial presented at 23rd Annual Scientific Meeting in Urologic Oncology (SUO) - Blue Earth Diagnostics, a Bracco company and recognized leader in the development and

United statesUnited kingdomSan diegoScintomics gmbKostenloser wertpapierhandelDavide gaudenBrianf chapinClare gidleyMike beyerPriscilla harlanUniversity of texas md anderson cancer centerDrug administrationStudy groupSam brown incBracco groupDivision of surgery

vimarsana © 2020. All Rights Reserved.